|Expense Ratio (net)||0.74%|
|Morningstar Risk Rating||★★★★★|
|Last Cap Gain||0.00|
|Inception Date||Dec 16, 1985|
|Average for Category||N/A|
The decline in biotech stocks is momentary and we expect the industry to bounce back in the coming days. So consider investing in these three biotech mutual funds.
Broadly encouraging economic conditions, favorable policies and a higher number of approvals from the FDA makes healthcare mutual funds a hotbed of money.